Addex Therapeutics Ltd

Company Description

---

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.

Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.

Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is in a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID).

Year founded

---

2002

Served area

---

Worldwide

Headcount

---

28

Headquarters

---

Chemin des Aulx 12, 1228 Plan-les-Ouates – Switzerland

Shares outstanding

---

65,272,952

IPO

---

May 22, 2007

Stock exchange(s)

---

SIX Swiss Exchange